Cargando…
Identification of Monobenzone as a Novel Potential Anti-Acute Myeloid Leukaemia Agent That Inhibits RNR and Suppresses Tumour Growth in Mouse Xenograft Model
SIMPLE SUMMARY: The clinical treatment of acute myeloid leukaemia is still dominated by chemotherapy. Clinically used anti-leukaemia drugs have shortcomings such as myelosuppression, toxicity and drug resistance. Therefore, the need to develop other chemotherapeutic drugs to meet more clinical needs...
Autores principales: | Dong, Jingwen, Zhong, Tingting, Xu, Zhijian, Chen, Haiyi, Wang, Xianjun, Yang, Lili, Lou, Zhiyuan, Xu, Yuanling, Hou, Tingjun, Xu, Rongzhen, Zhu, Weiliang, Shao, Jimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564123/ https://www.ncbi.nlm.nih.gov/pubmed/36230632 http://dx.doi.org/10.3390/cancers14194710 |
Ejemplares similares
-
Rnr1, but not Rnr3, facilitates the sustained telomerase-dependent elongation of telomeres
por: Maicher, André, et al.
Publicado: (2017) -
Optimization of Monobenzone-Induced Vitiligo Mouse Model by the Addition of Chronic Stress
por: Dong, Jing, et al.
Publicado: (2023) -
The response of human myeloid leukaemia xenografts to human recombinant tumour necrosis factor.
por: Clutterbuck, R. D., et al.
Publicado: (1989) -
A glutaredoxin domain fused to the radical-generating subunit of ribonucleotide reductase (RNR) functions as an efficient RNR reductant
por: Rozman Grinberg, Inna, et al.
Publicado: (2018) -
Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
por: van den Boorn, Jasper G., et al.
Publicado: (2010)